Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination With Cobimetinib in Locally-Advanced or Metastatic Pancreatic Cancer

NCT05034627 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT05034627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05034627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination With Cobimetinib in Locally-Advanced or Metastatic Pancreatic Cancer
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2022
Completion date
June 3, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic adenocarcinoma, metastatic pancreatic adenocarcinoma, stage ii pancreatic cancer ajcc v8, stage iia pancreatic cancer ajcc v8, stage iib pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8